Omeros (NASDAQ:OMER) executives highlighted two “major successes” in the fourth quarter of 2025 that they said marked a ...
Novartis announced final two-year results from the phase III APPLAUSE-IgAN study of Fabhalta (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically significant, clinically ...
Access to education means little if girls are denied protection from harassment, cyber-bullying, and online sexual ...
The chemotherapy drug azacitidine, a frontline treatment for blood cancers such as myelodysplastic syndromes and acute ...
Ikarovec has presented preclinical evidence for IKAR-001, a dual-pathway gene therapy designed to combine complement ...
There’s a moment when a place goes from interesting to unforgettable. This is one of those places. Right along the California ...
Exercise physiologists (EPs) are increasingly recognised for their role in supporting people with lived experience of mental ...